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Photosensitivity is a main criterion for the diagnosis of
systemic lupus erythematosus (LE), and ultraviolet (UV)
irradiation plays a key role in the pathogenesis of
cutaneous LE. Patients with a tentative diagnosis of LE
are routinely tested for skin lesion development after
experimental UV irradiation, providing an ideal oppor-
tunity to evaluate early, preclinical events involved in
the pathogenesis of LE. Several reports have shown
expression of the cytokine-inducible nitric oxide synthase
(iNOS) in autoimmune diseases. Therefore, we investi-
gated the role of iNOS expression at mRNA and protein
level in the pathogenesis of LE lesions. Skin biopsies from
patients with different subtypes of LE were examined,
and iNOS expression was found in six of 18 biopsies from
cutaneous LE patients and two of three biopsies from
systemic LE patients. In biopsies taken 4–20 d after UV
It has long been known that in the majority of patients sufferingfrom one of the different subsets of lupus erythematosus (LE),skin lesions occur preferentially in sun-exposed areas (Cazenave,1851; Hutchinson, 1888). Thus, photosensitivity comprises oneof the American Rheumatism Association criteria for the
diagnosis of systemic LE (Tan et al, 1982). It has also been widely
demonstrated that artificial ultraviolet radiation (UVR), i.e., from visits
to tanning salons, induces or exacerbates the course of the disease
(Nobl, 1921; Stern and Docken, 1986) and phototesting has shown
that both UVA and UVB irradiation are capable of provoking skin
lesions in LE patients (Lehmann et al, 1990).
Epidermal keratinocytes are able to express enzymatic activities
leading to the formation of the small radical nitric oxide (NO). This
can serve as a mediator (e.g., regulating local blood flow or acting as
a neurotransmitter) but is also responsible for non-specific immune
defense mechanisms (Knowles and Moncada, 1994; Kro¨ncke et al,
1995). Indeed, UVR has been shown to modulate local NO production
by the constitutively expressed neuronal nitric oxide synthase (ncNOS)
(Deliconstantinos et al, 1995). Several studies have demonstrated that
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irradiation, epidermal iNOS expression was seen in all
patients (n J 10) after UVB and in four of 10 patients
provoked by UVA. In healthy controls (n J 8) epidermal
iNOS expression was detected 24 h after UV irradiation,
persisting for another day before subsiding on day 3. In
LE patients (n J 8) the exact reverse situation was seen:
an iNOS-specific signal was undetectable in keratinocytes
for 2 d after UV irradiation, but became positive on day
3 and persisted for up to 25 d in the evolving skin lesions.
Our findings demonstrate a time-restricted, UV-induced
iNOS expression in human skin; moreover, the results
indicate that both the kinetics of iNOS induction as well
as the time span of local iNOS expression may be critical
to the development of cutaneous LE lesions. Key words:
autoimmune disease/human skin/keratinocytes. J Invest Derma-
tol 111:149–153, 1998
another isotype of this family, the inducible nitric oxide synthase
(iNOS), is expressed by epidermal keratinocytes after endogenous and/
or exogenous stimuli and is invariably present in lesional skin of
psoriasis patients (Becherel et al, 1994; Kolb-Bachofen et al, 1994;
Bruch-Gerharz et al, 1996). In addition, it has been reported that
iNOS expression and enzymatic activity appear to play an important
role in the course of various autoimmune diseases (Kolb and Kolb-
Bachofen, 1992). This led us to investigate the role of iNOS during
the early onset of UV-induced lesion formation in cutaneous forms
of LE.
MATERIALS AND METHODS
Phototesting procedure The light sources used included an UVASUN 3000
unit high-pressure metal halide lamp (340–400 nm, Mutzhas, Munich, Germany)
for UVA phototesting, and an UV-800 unit lamp with fluorescent bulbs (285–
350 nm) Philips TL 20 W/12 (Waldmann, Villingen/Schwenningen, Germany)
for UVB phototesting. Irradiation output was monitored by means of an
UV-radiometer (Mutzhas UVAMETER, Munich, Germany) and Waldmann
UV-spectrometer. Minimal erythema dose (MED), threshold dose for immediate
pigment darkening, and minimal tanning dose were determined as previously
described (Ho¨lzle et al, 1987). For the provocative phototest, two areas
(5 3 8 cm) of uninvolved skin on the back were irradiated with single doses
of 100 J UVA per cm2 and 1.5 MED, respectively, daily for three consecutive
days. Test areas were evaluated until specific lesions appeared for up to 4 wk
after the last session of irradiation. Criteria for a positive provocative phototest
result required that induced lesions clinically resembled LE, histopathologic
findings were compatible with LE, and skin lesions developed slowly and
persisted for several days. None of the patients received any medication during
the testing period (Lehmann et al, 1990).
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Table I. Clinical data of the patient cohort biopsied for the
study
Sex
Average age at
Diagnosisa Number Male Female biopsy
SCLE 15 6 9 47.1
LET 13 6 7 41.1
DLE 13 8 5 48.7
SLE 3 2 1 58.6
aSCLE, subacute cutaneous lupus erythematosus; LET, lupus erythematosus tumidus;
DLE, discoid lupus erythematosus; SLE, systemic lupus erythematosus.
Selection and preparation of skin specimens Skin biopsies were taken
from genuine lesions of 21 patients with untreated LE, from uninvolved skin
of five patients, from 10 patients with LE lesions induced by UVA, and from
10 patients with LE lesions induced by UVB (Table I). The MED in LE
patients was 0.09 6 0.04 J per cm2, as compared with 0.1 6 0.03 J per cm2
in a control group. We also analyzed skin biopsies from eight healthy controls
and from eight LE patients 24, 48, and 72 h after a single dose of either UVA
(100 J per cm2) or UVB (1.5 MED). Biopsies were processed for indirect
immunohistochemistry, in situ hybridization, and reverse transcriptase polymerase
chain reaction.
Immunohistochemical procedure Seven micrometer frozen sections were
fixed with 0.2% glutaraldehyde, pH 7.4, for 10 min at room temperature,
followed by reduction of endogenous peroxidase activity with 0.03% hydrogen
peroxide in methanol for 30 min at 4°C. Non-specific binding was blocked
with 0.5% bovine serum albumin in 0.01 M phosphate buffered saline, pH 7.4,
for 1 h at room temperature. Tissue sections were incubated with a monoclonal
antibody (1:100) to mouse macrophages iNOS (Transduction Laboratories,
Lexington, KY) for 16 h at 4°C, followed by incubation with an affinity-
purified peroxidase-labeled goat anti-mouse IgG (1:100, Zymed, San Francisco,
CA). After using diaminobenzidine as a substrate, tissue sections were counter-
stained with hematoxylin and mounted. All reactions were performed in a
humidified chamber at 4°C and, for control purposes, the first monoclonal
antibody was either omitted or replaced by an irrelevant isotype-matched
reagent. These experiments consistently yielded negative results.
In situ hybridization
Preparation of digoxigenin-labeled mRNA probes iNOS cDNA (a generous gift
from Dr. C. Nathan, Cornell University, Medical College, New York) was
subcloned into transcription vectors pSPT 18 and pSPT 19 as described (Leitch
et al, 1994). After linearization of plasmid DNA with appropriate restriction
enzymes, digoxigenin-labeled RNA probes were synthesized by in vitro transcrip-
tion of cDNA. The size of digoxigenin-labeled RNA probes was checked on
a formaldehyde gel. After ethanol precipitation the riboprobe was resuspended
at 10 µg per µl in a buffer (pH 7.5) consisting of 10 mM Tris HCl and 1 mM
ethylenediamine tetraacetic acid.
Hybridization procedure Paraformaldehyde-fixed 7 µm cryostat sections were
incubated in 20 µl of hybridization solution consisting of 50% formamide, 5%
blocking reagent (both from Boehringer, Mannheim, Germany), 53sodium
citrate/chloride buffer, 0.1% N-laurylsarcosine, 0.02% sodium dodecyl sulfate,
100 mM Tris HCl (pH 7.4), 5 mM ethylenediamine tetraacetic acid, as well as
the heat-denatured probe (final concentration: 0.5 µg per µl). Hybridization
was carried out overnight at 40°C in a humidified chamber after addition of
the heat-denatured probe. Every anti-sense and, for control purposes, every
sense probe was hybridized with at least two sections of the same biopsy. After
the hybridization, nonhybridized probes were removed by several washing
procedures with 23sodium citrate/chloride buffer, 0.1% sodium dodecyl sulfate
at 50°C. Slides were then incubated with a 1:1000 dilution of an alkaline-
phosphatase-labeled anti-digoxigenin antibody (Boehringer) overnight at 4°C.
Staining of the tissue sections was performed using 5-bromo-4-chloro-3-indolyl
phosphate toluidine and nitroblue tetrazolium salt as substrate (Boehringer).
Reverse transcriptase polymerase chain reaction Fresh skin biopsies were
flash frozen in liquid nitrogen and total RNA extraction was performed
essentially as previously described (Schulz et al, 1993). First strand cDNA was
prepared from 1 µg of total RNA using Avian moloney leukemia virus reverse
transcriptase (Boehringer) under the conditions suggested by the supplier. After
reverse transcription to cDNA, amplification was carried out by polymerase
chain reaction with 15 mM MgCl2 using Taq polymerase (Gibco Laboratories,
Grand Island, NY) in a final volume of 50 µl. Polymerase chain reaction was
performed with primers specific for iNOS (ATGCCAGATGGCAGCATC
Figure 1. Expression of iNOS in skin specimens of genuine LE by
immunohistochemistry and in situ hybridization. In genuine lesional skin
the epidermal keratinocytes of the basal layer show a strong and specific signal
for (a) iNOS protein (brown signal) and (b) iNOS mRNA (blue signal) in a
band-like pattern. Scale bar: 50 µm.
Table II. A large proportion of lesional biopsies from LE
patients were positive for iNOS expression
Anti-iNOS
monoclonal antibody In situ hybridization
1 – 1 –
Genuine lesional skin
Cutaneous LE 6/18a 12/18 6/18 12/18
Systemic LE 2/3 1/3 2/3 1/3
UV induced lesions
UVA 4/10 6/10 4/10 6/10
UVB 10/10 0/10 10/10 0/10
Non-lesional skin 0/5 5/5 0/5 5/5
aNumbers represent positive or negative iNOS expression per total biopsies tested.
AGA and TTTCCAGGCCCATTCTCCTGC), yielding a 391 bp product;
and separately for glyceraldehyde-3-phosphatedehydrogenase (ATTCCA
TGGCACCGTCAAGGCT and TCAGGTCCACCACTGACACGTT) to
yield a 550 bp product. Cycle times were 30 s at 94°C, 45 s at 62°C, and 30 s
at 72°C for 37 cycles.
RESULTS
Expression of iNOS in genuine and UV-induced skin lesions of
LE The expression of iNOS at mRNA and protein level was studied
in biopsies of genuine lesional skin from 21 patients with different
subtypes of LE (Table I). Six of 18 lesional skin biopsies from patients
with cutaneous LE and two of three patients with systemic LE showed
expression of both iNOS mRNA and protein in the basal layer of the
epidermis (Fig 1a, b), whereas iNOS expression was not found in any
of the five non-lesional biopsies (Table II).
We also screened lesional skin biopsies of LE patients after photo-
provocation testing for diagnostic purposes. Biopsies were taken 4–
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Figure 2. Different kinetics of iNOS
protein expression after UVB irradiation
(1.5 MED) in skin specimens of healthy
controls and LE. In all controls (a–c)
immunohistochemistry shows iNOS protein
expression in the basal layer of epidermal
keratinocytes (brown signal) 24 h after UVR
(a). In this particular control iNOS protein is
still strongly expressed 48 h after UVR in
epidermal keratinocytes (b). Seventy-two
hours after UVR, expression of iNOS protein
is no longer detected in the epidermis of any
control (c). In the epidermis of all LE patients
(d–f) no iNOS protein expression is found
24 h after UVR (d). Immunohistochemistry
reveals weak iNOS protein expression 48 h
after UVR in the basal layer of the epidermis
(brown signal) in this skin specimen (e). iNOS
protein is significantly expressed in epidermal
keratinocytes of all LE patients 72 h after
UVR (f). Scale bar: 50 µm.
25 d after the last UVA or UVB treatment. All of the 10 patients with
cutaneous LE responding to UVB (1.5 MED) irradiation with lesion
formation and four of 10 patients after UVA (100 J per cm2) exposure
demonstrated iNOS expression in the basal layer of the epidermis
(Table II).
Short-term expression of iNOS in skin biopsies of healthy
controls after UV irradiation Controls (n 5 8) who had once
received a single dose of UVA (100 J per cm2) or UVB (1.5 MED)
irradiation were biopsied on days 1, 2, or 3 after exposure. As shown
in Figs 2(a–c) and 3(a–c), iNOS mRNA and protein expression were
seen on day 1 and were weak to borderline on day 2, but were not
detectable on day 3. This expression pattern was observed in all controls
irrespective of UVR source in the basal layer of the epidermis
(Table III). Skin biopsies from three controls taken on days 1 and
3 were processed for iNOS-specific mRNA detection by reverse
transcriptase polymerase chain reaction (Fig 4a), further confirming
the iNOS expression pattern obtained above.
Aberrant timing of iNOS induction after UV irradiation in
cutaneous LE Untreated patients with different forms of cutaneous
LE (n 5 8) were irradiated with UVA (100 J per cm2) or UVB (1.5
MED) on uninvolved areas, biopsied exactly as described for the
healthy controls, and processed accordingly. Figures 2(d–f) and 3(d–
f) demonstrate the time course of iNOS expression in these patients
to be exactly reversed: no iNOS expression on day 1, no or borderline
iNOS expression on day 2, and a significantly increased expression of
iNOS was detectable on day 3 in the basal layer of the epidermis. This
pattern was observed in all patients investigated, regardless of the
irradiation source. Three LE patients were biopsied on days 1 and 3
and these specimens were processed for reverse transcriptase polymerase
chain reaction. As shown in Fig 4(b), the reverse time course of iNOS
expression could be confirmed.
Thus, the results indicate a delayed induction of epidermal iNOS
expression by UVR in LE patients (on day 3) as compared with
healthy controls.
DISCUSSION
Several lines of investigation have demonstrated that iNOS expression
is associated with a large number of human inflammatory diseases, as
well as with autoimmune disorders such as rheumatoid arthritis and
multiple sclerosis (Sakurai et al, 1995; Bagasra et al, 1995). Furthermore,
NO generation by iNOS appears to be critical for disease manifestation
in animal models of type 1 diabetes mellitus (Kleemann et al, 1993;
Rothe et al, 1994). Recent studies have shown that MRL/lpr mice
developing a spontaneous autoimmune disease resembling systemic LE
(Cohen and Eisenberg, 1991) excrete significantly higher concentrations
of urinary nitrite/nitrate as an indicator of increased NO generation
(Weinberg et al, 1994).
As human LE is associated with UV-inducible cutaneous lesions
(Lehmann et al, 1990), we have investigated these skin lesions for the
expression of iNOS. Indeed, when studying genuine and UV-induced
LE lesions we found a significantly increased expression of iNOS in
these biopsies, in agreement with the findings in MRL/lpr mice
(Weinberg et al, 1994); however, the results presented here suggest for
the first time that the exact timing of iNOS expression is critical for
disease manifestation, rather than merely the presence of this enzyme.
Expression of iNOS seems to represent a normal response of human
skin towards UVR, as all healthy donors showed the same response
pattern with differences only in signal intensities, irrespective of UVR
source. Interestingly, the time course of iNOS expression correlated
with UV-induced erythema formation, which normally peaks at about
24 h after irradiation, lasts for 2 d, and disappears on day 3 (Gilchrest
et al, 1981). NO is known to enhance local blood flow and to induce
edema formation (Thiemermann, 1994), both of which are hallmarks
of the human ‘‘sunburn’’ reaction. Thus, it appears likely that local
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Figure 3. Different kinetics of iNOS
mRNA expression after UVB irradiation
(1.5 MED) in skin specimens of healthy
controls and LE. Accordingly, in all controls
(a–c) in situ hybridization reveals iNOS
mRNA expression in the basal layer (blue
signal) of the epidermis 24 h after UVR (a).
In this single skin specimen significantly less
iNOS mRNA expression is detectable in
epidermal keratinocytes 48 h after UVR (b).
iNOS mRNA is no longer expressed 72 h
after UVR in the epidermis of any control.
In LE patients (d–f) iNOS mRNA expression
is not found in the epidermis 24 h after
UVR by in situ hybidization (d). Borderline
expression of iNOS mRNA is detectable 48 h
after UVR by epidermal keratinocytes (blue
signal) in some skin specimens of LE patients.
(f) In situ hybridization shows iNOS mRNA
expression in the basal layer of epidermal
keratinocytes 72 h after UVR of all LE
patients. Scale bar: 50 µm.
Table III. Aberrant timing of iNOS expression after UVR in
LE patients as compared with healthy controls
Anti-iNOS
monoclonal antibody In situ hybridization
UVA UVB UVA UVB
Healthy controls
24 h after UVR 3/3a 3/3 3/3 3/3
48 h after UVR 3/3b 3/3b 1/3b 2/3b
72 h after UVR 0/2 0/2 0/2 0/2
LE patients
24 h after UVR 0/4 0/4 0/4 0/4
48 h after UVR 2/4b 2/4b 2/4b 4/4b
72 h after UVR 4/4 3/3 4/4 3/3
aNumbers represent positive iNOS expression per total biopsies tested.
bBorderline iNOS expression is seen 48 h after UVR as compared with the other
time points.
expression of iNOS and increased NO production is one of the
molecular mechanisms of erythema formation.
The delayed and prolonged expression of iNOS by keratinocytes
after UVA or UVB irradiation in patients with cutaneous LE, in
contrast to the time course of iNOS expression in healthy controls, is
a striking feature. Further studies must clarify whether this is due to
impaired regulation of iNOS induction/expression or due to an indirect
effect in delayed or faulty cytokine expression profiles; however, our
results demonstrate for the first time an early molecular marker for
photosensitivity associated with cutaneous LE. It may serve as a
diagnostic tool, enabling the assessment of photosensitivity reaction
from simple phototest protocols, instead of the currently used provoca-
tion tests that require lesion development as diagnostic end points. In
Figure 4. Confirmation of the timing difference between healthy
controls and LE by reverse transcriptase polymerase chain reaction of
iNOS mRNA from skin biopsies after UVB irradiation (1.5 MED).
(A) iNOS mRNA is present in skin biopsies 24 h after UVR in all three
controls, but is not expressed by epidermal keratinocytes 72 h after UVR in
any control. (B) In contrast, iNOS mRNA is not detectable 24 h after UVR
in any LE patient, but is expressed 72 h after UVR in all three LE patients.
addition to serving as a diagnostic marker, delayed iNOS expression
may also represent a target for therapeutic intervention. Further
investigations will center on the question of whether exogenous
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addition of NO via chemical donors will deter or ameliorate UV-
induced skin lesions in this disease.
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